Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Summary

This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 administered orally in subjects with advanced hematologic malignancies.

Timeline

Start

2025-05-01

Primary completion

2027-04

Completion

2028-06

Drugs

Indications